Cat. No.: HY-N16691

Acrovestone

Acrovestone is a natural acetophenone dimer isolated from Acronychia pedunculata. Acrovestone inhibits 5-lipoxygenase/mPGES-1 with IC₅₀ values of 2.7 µM and 1.1 µM, respectively. Acrovestone inhibits TbPTR1, TbDHFR, and hDHFR. Acrovestone inhibits ERK1/2, increases p38, promotes Akt/FoxO3a, inhibits BIM, upregulates Bcl-2/Bcl-xL, reduces caspase-9/3 cleavage, and modulates caspase-7. Acrovestone can serve as an antitumor compound that inhibits the growth of various cancer cells. Acrovestone can be used in research on cancers such as leukemia, cervical cancer, lung cancer, and colorectal cancer, as well as neurodegenerative diseases.

For research use only. We do not sell to patients.

CAS No.: 24177-16-0
Formula: C₃₂H₄₂O₈
Molecular Weight:554.67

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Acrovestone Chemical Structure

CAS No.: 24177-16-0

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]

5-Lipoxygenase

2.7 μM (IC₅₀)

mPGES-1

1.1 μM (IC₅₀)

TbPTR1

36.8 μM (EC₅₀)

TbDHFR

2.1 μM (IC₅₀)

hDHFR

19.8 μM (IC₅₀)

ERK1

ERK2

p38

Akt

FOXO3a

Bim

Bcl-2

Bcl-xL

Caspase-9

Caspase-3

Caspase-7

All Lipoxygenase Isoforms :

All ERK Isoforms :

All p38 MAPK Isoforms :

All Akt Isoforms :

All FOXO Isoforms :

FOXO1
FOXO3

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Jurkat	IC50	4.9 μM	Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay. Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.	39073310
NALM-6	IC50	7.8 μM	Antiproliferative activity against human NALM6 B cell precursor leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay. Antiproliferative activity against human NALM6 B cell precursor leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.	39073310
K562	IC50	3.8 μM	Antiproliferative activity against human K562 erythroid leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay. Antiproliferative activity against human K562 erythroid leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.	39073310
HPBALL	IC50	2.71 μM	Antiproliferative activity against human HPB-ALL T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay. Antiproliferative activity against human HPB-ALL T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.	39073310
HeLa	IC50	0.77 μM	Acrovestone (compound 4 assignment) antiproliferative activity against human cervical cancer HeLa cells assessed as viability reduction incubated 72 hrs by MTT assay. Acrovestone (compound 4 assignment) antiproliferative activity against human cervical cancer HeLa cells assessed as viability reduction incubated 72 hrs by MTT assay.	36302543
A549	IC50	1.13 μM	Acrovestone (compound 4 assignment) antiproliferative activity against human lung carcinoma A549 cells assessed as viability reduction incubated 72 hrs by MTT assay. Acrovestone (compound 4 assignment) antiproliferative activity against human lung carcinoma A549 cells assessed as viability reduction incubated 72 hrs by MTT assay.	36302543
A549	IC50	6.1 μM	Antiproliferative activity against human A549 lung carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay. Antiproliferative activity against human A549 lung carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay.	31550158
MDA-MB-231	IC50	6.4 μM	Antiproliferative activity against human MDA-MB-231 triple-negative breast cancer cells assessed after 72 hrs incubation by sulforhodamine B assay. Antiproliferative activity against human MDA-MB-231 triple-negative breast cancer cells assessed after 72 hrs incubation by sulforhodamine B assay.	31550158
KB	IC50	4.9 μM	Antiproliferative activity against human KB cervical carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay. Antiproliferative activity against human KB cervical carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay.	31550158
SH-SY5Y	IC50	6.12 μM	Cytotoxicity against human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs incubation by CCK-8 assay. Cytotoxicity against human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs incubation by CCK-8 assay.	40451969
SH-SY5Y	EC50	0.58 μM	Neuroprotective activity against 10 mM glutamate-induced excitotoxicity in human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs pretreatment and 24 hrs glutamate exposure by CCK-8 assay. Neuroprotective activity against 10 mM glutamate-induced excitotoxicity in human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs pretreatment and 24 hrs glutamate exposure by CCK-8 assay.	40451969
HCT-116	IC50	0.24 μM	Antiproliferative activity against human HCT-116 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay. Antiproliferative activity against human HCT-116 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay.	39073310
RKO	IC50	1.54 μM	Antiproliferative activity against human RKO colon cancer cells assessed as viability reduction by MTT assay. Antiproliferative activity against human RKO colon cancer cells assessed as viability reduction by MTT assay.	39073310
SW480	IC50	5.3 μM	Antiproliferative activity against human SW480 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay. Antiproliferative activity against human SW480 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay.	39073310
MCF-10A	IC50	15.3 μM	Antiproliferative activity against human MCF-10A breast epithelial cells assessed as viability reduction by MTT assay. Antiproliferative activity against human MCF-10A breast epithelial cells assessed as viability reduction by MTT assay.	39073310
DU-145	IC50	0.93 μM	Cytotoxicity of Acrovestone against human DU145 prostate cancer cells assessed as viability reduction after 48 hrs incubation by MTS assay. Cytotoxicity of Acrovestone against human DU145 prostate cancer cells assessed as viability reduction after 48 hrs incubation by MTS assay.	22708987
A2058	IC50	0.38 μM	Cytotoxicity of Acrovestone against human A2058 melanoma cells assessed as viability reduction after 48 hrs incubation by MTS assay. Cytotoxicity of Acrovestone against human A2058 melanoma cells assessed as viability reduction after 48 hrs incubation by MTS assay.	22708987

In Vitro

Anti-cancerApoptosisGlutamate Release or ReceptorsInnate ImmunityLipid Inflammatory MediatorsLipid mediators of inflammationParasitic InfectionNucleotide Metabolism

Anti-cancer

Acrovestone (24 h) shows anti-proliferative activity against human leukemia cell lines Jurkat, NALM6, K562, and HPB-ALL with IC₅₀ values of 4.9, 7.8, 3.8, and 2.71 µM, respectively, while not inhibiting PBMNCs at >50 µM^[2].
Acrovestone (0.195-100 µg/mL; 72 h) exhibits anti-proliferative activity against HeLa and A549 cells with IC₅₀ values of 0.77 µM and 1.13 µM (as compound 5) or 5.1 µM and 11.8 µM (as compound 4), respectively^[4].
Acrovestone (72 h) inhibits proliferation of A549, MDA-MB-231, KB, and KB-VIN human tumor cells with IC₅₀ values of 6.1, 6.4, 4.9, and 4.4 µM, respectively^[7].
Acrovestone has potent anti-proliferative activity against HCT-116 (IC₅₀ 0.24 μM), RKO (IC₅₀ 1.54 μM), and SW480 (IC₅₀ 5.3 μM) cancer cells in the MTT assay, and weaker activity against MCF-10A (IC₅₀ 15.3 μM)^[9].
Acrovestone (dose-dependent; 48 h) shows potent cytotoxicity against DU145 human prostate cancer cells with an IC₅₀ of 0.93 μM^[10].
Acrovestone (dose-dependent; 48 h) shows potent cytotoxicity against A2058 human melanoma cells with an IC₅₀ of 0.38 μM^[10].

Anti-cancer

Apoptosis

Glutamate Release or Receptors

Acrovestone (0.1-5 µM; 24 h) modulates glutamate-induced signaling in SH-SY5Y cells by suppressing ERK1/2 and caspase activation while promoting Akt/FoxO3a, Bcl-2, and Bcl-xL, with optimal effects at 0.1-1 µM^[8].

Anti-cancer

Glutamate Release or Receptors

Acrovestone (0.1-5 µM; 24 h) protects SH-SY5Y neuroblastoma cells against 10 mM glutamate-induced cytotoxicity with a neuroprotective EC₅₀ of 0.58 µM^[8].

Innate Immunity

Lipid Inflammatory Mediators

Acrovestone (2.7 μM; 10 min) inhibits isolated human recombinant 5-LO in a cell-free assay with an IC₅₀ of 2.7 μM^[1].
Acrovestone (2.3 μM; 15 min) inhibits 5-LO product formation in intact human neutrophils with an IC₅₀ of 2.3 μM^[1].

Lipid mediators of inflammation

Acrovestone (1.1 μM; 15 min) inhibits mPGES-1 in a cell-free assay using A549 microsomal fractions with an IC₅₀ of 1.1 μM^[1].

Parasitic Infection

Nucleotide Metabolism

Acrovestone (50-100 µM; 20 min) is a dual inhibitor of recombinant TbPTR1 (EC₅₀ 36.8 µM) and TbDHFR (IC₅₀ 2.1 µM), also inhibits hDHFR (IC₅₀ 19.8 µM), and shows no inhibition of LmPTR1 up to 50 µM^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

HeLa and A549 cell lines
Concentration:

0.195, 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100 µg/mL
Incubation Time:

72 h
Result:

Exhibited anti-proliferative activity against HeLa and A549 cells, with IC₅₀ values of 0.77 µM and 1.13 µM, respectively.

Cell Viability Assay^[8]

Cell Line:

human neuroblastoma SH-SY5Y cells
Concentration:

0.1, 0.5 µM (cytotoxicity); 0.1, 0.5, 1, 5 µM (protection)
Incubation Time:

24 h
Result:

Enhanced cell survival by 28% at 0.5 µM.
Not cytotoxic with IC₅₀ 6.12 µM.
Neuroprotective EC₅₀ was 0.58 µM in the SH-SY5Y model.
At 5 µM, the cell protective effect was abolished.
Glutamate induced rounded cell shape, whereas pre-exposure at 0.5 and 0.1 µM preserved normal morphology.

Western Blot Analysis^[8]

Cell Line:

human neuroblastoma SH-SY5Y cells
Concentration:

0.1, 0.5, 1, 5 µM
Incubation Time:

24 h
Result:

Dose-dependently reduced glutamate-induced ERK1/2 phosphorylation.
Attenuated the glutamate-induced decrease in p38 phosphorylation levels
Dose-dependently increased Akt phosphorylation.
Increased the level of glutamate-induced FoxO3a phosphorylation.
Slightly inhibited the glutamate-induced increase in Bim levels.
Glutamate reduced the expression of Bcl-2 and Bcl-xL, whereas the addition of Acrovestone at concentrations of 0.1 μM and 0.5 μM upregulated the expression of Bcl-2 and Bcl-xL, which had been reduced by glutamate.
Bax was slightly suppressed and the Bcl-2/Bax ratio was restored.
Suppressed caspase-9 and cleaved caspase-9 dose-dependently and decreased the cleaved caspase-9/caspase-9 ratio.
Caspase-3 effect was most pronounced at 0.5 and 1 µM.
Caspase-7 was slightly increased at 0.1 and 0.5 µM.
At 0.1-1 µM, reduced cleaved caspase-3 and -7 and their ratios, whereas at 5 µM, increased caspase-7 expression and abolished protection.

Related Protocols :

Apoptosis Solutions

Chemical Information

CAS No. 24177-16-0
Appearance Solid
Molecular Weight 554.67
Formula C₃₂H₄₂O₈
Color Light yellow to yellow
SMILES

O=C(C)C1=C(O)C(C(CC(C)C)C2=C(C(C(C)=O)=C(C(C/C=C(C)\C)=C2O)OC)O)=C(O)C(C/C=C(C)\C)=C1O
Structure Classification
- Phenols
- Ketones, Aldehydes, Acids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Svouraki A, et al. Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. Journal of natural products. 2017 Mar 24;80(3):699-706. [Content Brief]

[2]. Ito C, et al. Acetophenones Isolated from Acronychia pedunculata and their Anti-proliferative Activities. Natural product communications. 2016 Jan;11(1):1934578X1601100125.

[3]. De Silva LB, et al. Demethylacrovestone from Achronychia pedunculata fruits. Phytochemistry. 1991 Jan 1;30(5):1709-10.

[4]. Wisetsai A, et al. Acrotrione B, a Prenylated and Highly Oxidized Xanthenoid with Antibacterial and Anti-proliferative Activities from the Roots of Acronychia pedunculata. Planta medica. 2023 Apr;89(4):416-422.

[5]. Possart K, et al. In silico and in vitro search for dual inhibitors of the trypanosoma brucei and leishmania major pteridine reductase 1 and dihydrofolate reductase. Molecules. 2023 Nov 10;28(22):7526.

[6]. Ramya S, et al. In Silico Analysis of Selective Bioactive Compounds from Acronychia Pedunculata as a Potential Inhibitor of HER2 in Colorectal Cancer. J Pharm Bioallied Sci. 2024 Apr;16(Suppl 2):S1281-S1286.

[7]. Miyake K, et al. Prenylated Acetophloroglucinol Dimers from Acronychia trifoliolata: Structure Elucidation and Total Synthesis. J Nat Prod. 2019 Oct 25;82(10):2852-2858. [Content Brief]

[8]. Worasrihirun P, et al. Neuroprotective effects of acetophenone dimers from Acronychia pedunculata on human neuroblastoma SH-SY5Y cells in glutamate-induced apoptosis. Journal of natural medicines. 2025 Jul;79(4):938-949.

[9]. Yang ZZ, et al. Prenylated Acetophenone Derivatives from the Leaves of Acronychia pedunculata and Their Anti-Proliferative Activities. Chemistry & biodiversity. 2024 Nov;21(11):e202401027.

[10]. Kouloura E, et al. Cytotoxic prenylated acetophenone dimers from Acronychia pedunculata. Journal of natural products. 2012 Jul 27;75(7):1270-6. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Acrovestone

All Lipoxygenase Isoforms

All ERK Isoforms

All p38 MAPK Isoforms

All Akt Isoforms

All FOXO Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms